Please login to the form below

Not currently logged in
Email:
Password:

James Murdoch to step down from GSK's board

Announcement follows 2011’s damaging revelations of phone hacking at UK newspaper the News of the World

James Murdoch will step down from GlaxoSmithKline's (GSK) board of directors after the pharma company's annual general meeting later this year.

Murdoch is chairman and chief executive of the News Corporation media empire, which faced a series of damaging revelations during 2011 over phone hacking at its UK newspaper the News of the World.

GSK's chairman Sir Christopher Gent said: “James has taken this decision to focus on his current duties as non-executive chairman of BSkyB, and following his decision to re-locate to the US, as chairman and chief executive, international, of News Corporation.

“On behalf of the board, I would like to thank James for the very strong contribution he has made since he was appointed in 2009 and wish him well for the future.”

Other planned changes to GSK's board will see Sir Crispin Davis, Sir Robert Wilson and Larry Culp step down in 2013.

Sir Crispin will be succeeded by Tom de Swaan, who will take over as chairman of the remuneration committee with effect from January 1, 2013, and Judy Lewent, who will take over as chair of the audit and risk committee with effect from the same date.

Meanwhile Sir Deryck Maughan will succeed Sir Robert as senior independent non-executive director with effect from the closure of GSK's annual general meeting in 2013.

31st January 2012

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?...
Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...